Why store cord blood?

Today, cord blood stem cells have been used in the treatment of over 80 life threatening diseases.1 There have been over 40,000 transplants2 worldwide using cord blood in place of bone marrow for conditions including:

  • Solid tumors
  • Cancers
  • Genetic diseases
  • Immune deficiencies
  • Blood disorders & leukemias


What are the emerging treatments where cord blood may be used?

Scientific research is evaluating how cord blood cells may provide new therapies for a broad number of diseases for which there is no effective treatment today. While regenerative medicine has exciting potential, its prospects remain dependent on the success of ongoing research around the world.


Conditions with clinical trials ongoing:3

  • Autism
  • Cerebral Palsy
  • Type-1 Diabetes
  • Stroke


Importantly, a number of the new cord blood cell therapies being researched anticipate requiring cells directly from the patient being treated (i.e. autologous therapies).


Emerging cord blood technologies

Advancements in technology may enable the number of cells available from cord blood collections to be expanded.


The important benefits of cell expansion would be:7


  • Extending the period over which cord blood stem cells may be used, as treatments for adults require more stem cells than treatments for a child
  • Increasing the potential number of therapies from one unit of cord blood

Why store cord tissue?

Research suggests that cord tissue mesenchymal stem cells (MSCs) have the ability to develop into structural and connective tissue. This important characteristic means that they could potentially be used to treat more conditions than cord blood alone can treat.6


Today, there are 70+ ongoing trials that are investigating the potential of MSCs to help treat a variety of medical conditions including:3

  • Stroke
  • Multiple Sclerosis
  • Rheumatoid Arthritis
  • Wound Repair


Storing cord tissue today may provide future health options for your child and your family.


Mesenchymal Stem Cells (MSCs) and especially those from umbilical cord tissue, are showing potential to treat COVID-19 as they have been observed to exert a broad set of potential benefits, including improving the lung microenvironment, inhibiting immune overreaction and promoting tissue repair to improve lung function.

1. Matsumoto M.M. and Matthews K.R. A Need for Renewed and Cohesive US Policy on Cord Blood Banking. Stem Cell Rev. 2015 Dec;11(6):789-97. doi: 10.1007/s12015-015-9613-9.
2. Ballen K. Update on umbilical cord blood transplantation [version 1; referees: 2 approved]. F1000Research 2017, 6(F1000 Faculty Rev):1556 (doi: 10.12688/f1000research.11952.1)
3. https://clinicaltrials.gov/
4. Bioinformant: Complete 2017-18 Cord Blood Banking Industry Report www.Bioinformant.com.
5. https://clinicaltrials.gov, www.australianclinicaltrials.gov.au
6. Omar et al, Umbilical Cord Mesenchymal Stem Cells: The New Gold Standard for Mesenchymal Stem Cell-Based Therapies? Tissue Eng Part B Rev. April 2014 (Epub ahead of print).
7. Nietfeld JJ, Pasquini MC, Logan BR,Verter F, Horowitz MM. Lifetime probabilities of hematopoietic stem cell transplantation in the US. Biol Blood Marrow transplant. Mar 2008; 14(3): 316-3